We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
ADLM 2025
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid Point-of-Care COVID-19 Test Delivers Digital Results in 15 Minutes

By LabMedica International staff writers
Posted on 31 Jul 2025

A digital test can detect COVID-19 antigens in symptomatic individuals in about 15 minutes at doctors' offices, urgent care centers, retail clinics, and other convenient points of care.

The BD Veritor System for SARS-CoV-2 from BD (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) is a chromatographic, digital lateral flow immunoassay intended for the direct detection of the presence or absence of SARS-CoV-2 antigens in respiratory specimens taken from patients with signs and symptoms who are suspected of COVID-19, or taken from asymptomatic individuals being tested serially. The rapid chromatographic digital immunoassay provides results from nasal swab specimens from patients within six days of symptom onset.


Image: The BD Veritor System for SARS-CoV-2 delivers easy-to-read results using BD Veritor Plus Analyzer (Photo courtesy of BD)
Image: The BD Veritor System for SARS-CoV-2 delivers easy-to-read results using BD Veritor Plus Analyzer (Photo courtesy of BD)

The test delivers objective, easy-to-read results using the BD Veritor Plus Analyzer, which provides rapid diagnostic testing in a convenient, portable instrument. The BD Veritor Plus Analyzer delivers reliable results promptly, enabling quick diagnosis and treatment of patients with an easy-to-read, portable device. It provides diagnostic testing where and when patients need it, offering reliable, rapid results for a variety of respiratory tract infections.

BD has now received U.S. Food and Drug Administration (FDA) 510(k) clearance for the BD Veritor System for SARS-CoV-2. The test, which is intended for use in CLIA-waived environments, has been available under Emergency Use Authorization (EUA) from the FDA since September 2020. The new 510(k) clearance will eventually replace the current EUA version of the test, starting in early fall 2025.

"This FDA clearance is part of our ongoing commitment to support health care providers with reliable, rapid diagnostic tools," said Nikos Pavlidis, worldwide president of BD Diagnostic Solutions. "The BD Veritor System for SARS-CoV-2 has proven to be a reliable COVID-19 test with a streamlined workflow and clear digital results, helping clinicians make confident and timely decisions that can help improve patient outcomes."

Related Links:
BD


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gel Cards
DG Gel Cards
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit

Latest Molecular Diagnostics News

Comprehensive Genomic Testing Reveals Treatment Targets In 90% Of Advanced Solid Tumors
31 Jul 2025  |   Molecular Diagnostics

Blood Tests Show Potential for Colorectal Cancer Detection
31 Jul 2025  |   Molecular Diagnostics

New Nanotechnology Efficiently Unzips DNA for Quick and Easy Genetic Testing
31 Jul 2025  |   Molecular Diagnostics